Showing 4 posts of 4 posts found.


FDA expands approval of Genentech’s Xofluza for post-exposure prevention of influenza

November 24, 2020
Manufacturing and Production, Sales and Marketing FDA, Xofluza, influenza

Genentech has secured FDA approval for Xofluza (baloxavir marboxil) for the post-exposure prevention of influenza in patients at least 12 …


FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza

October 18, 2019
Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma

Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …


Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial

September 2, 2019
Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma

Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …


First novel, single-dose flu drug approved in US in almost 20 years

October 25, 2018
Sales and Marketing FDA, Shionogi, Xofluza, flu, influenza, pharma

The FDA has announced that it has approved the first single-dose flu drug with a novel mechanism of action in …

Latest content